| A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma | Elranatamab | — | Not yet recruiting | Pfizer | Nov 9, 2026 |
| Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | Elranatamab | Phase 2 | Not yet recruiting | PETHEMA Foundation | Oct 28, 2026 |
| RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab | Elranatamab | — | Not yet recruiting | The Royal Wolverhampton Hospitals NHS Trust | Oct 23, 2026 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma | Teclistamab | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | Oct 22, 2026 |
| A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments | Elranatamab | Phase 4 | Not yet recruiting | Pfizer | Oct 19, 2026 |
| Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma | Idecabtagene vicleucel | Not applicable | Not yet recruiting | Centre Henri Becquerel | Oct 1, 2026 |
| The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE. | Belantamab mafodotin | Phase 2 | Not yet recruiting | Medical Association for the Study of Cancer Biology and Treatment | Sep 28, 2026 |
| Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) | Belantamab mafodotin | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | Sep 21, 2026 |
| Teclistamab In Waldenstrom's Macroglobulinemia | Teclistamab | Phase 2 | Not yet recruiting | Massachusetts General Hospital | Aug 28, 2026 |
| Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma | Elranatamab | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Aug 27, 2026 |
| A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A | Elranatamab | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Aug 26, 2026 |
| Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma. | Teclistamab | Phase 2 | Not yet recruiting | Odense University Hospital | Aug 11, 2026 |
| Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. | Belantamab mafodotin | Phase 2 | Not yet recruiting | Polish Myeloma Consortium | Aug 6, 2026 |
| A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease | Teclistamab | Phase 3 | Not yet recruiting | Polish Myeloma Consortium | Jul 31, 2026 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma | Teclistamab | Phase 3 | Recruiting | AbbVie | Jul 27, 2026 |
| Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma | Ciltacabtagene autoleucel | Phase 1 | Recruiting | Weill Medical College of Cornell University | Jul 24, 2026 |
| TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) | Belantamab mafodotin | Phase 1 | Not yet recruiting | Montefiore Medical Center | Jul 22, 2026 |
| Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney Transplantation | Teclistamab | Early phase 1 | Not yet recruiting | West China Hospital | Jul 15, 2026 |
| Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90% | Teclistamab | Phase 4 | Not yet recruiting | West China Hospital | Jul 8, 2026 |
| GMMG-HD11/DSMM XXI/64007957MMY3010 | Teclistamab | Phase 3 | Not yet recruiting | University of Heidelberg Medical Center | Jun 26, 2026 |
| Delayed Toxicities Post-CAR-T | Ciltacabtagene autoleucel | — | Recruiting | Icahn School of Medicine at Mount Sinai | Jun 24, 2026 |
| HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV | Elranatamab | Phase 1 | Recruiting | University of Illinois Chicago | Jun 15, 2026 |
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma | Elranatamab | Phase 2 | Recruiting | SCRI Development Innovations, LLC | Jun 10, 2026 |
| Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma | Belantamab mafodotin | — | Not yet recruiting | PETHEMA Foundation | Jun 9, 2026 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma | Belantamab mafodotin | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | May 29, 2026 |
| Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma | Belantamab mafodotin | Phase 2 | Not yet recruiting | GlaxoSmithKline | May 29, 2026 |
| A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment | Belantamab mafodotin | Phase 1 | Not yet recruiting | GlaxoSmithKline | May 27, 2026 |
| BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma | Ciltacabtagene autoleucel | Not applicable | Recruiting | Universitätsklinikum Hamburg-Eppendorf | May 4, 2026 |
| A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers | Idecabtagene vicleucel | Phase 1 | Recruiting | Dispatch Biotherapeutics | Apr 22, 2026 |
| Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma | Idecabtagene vicleucel | Phase 1 / Phase 2 | Recruiting | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | Mar 17, 2026 |
| Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma | Idecabtagene vicleucel | Phase 1 | Recruiting | Hadassah Medical Organization | Jan 12, 2026 |
| Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma | Ciltacabtagene autoleucel | Phase 1 | Recruiting | Washington University School of Medicine | Sep 30, 2025 |
| Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) | Ciltacabtagene autoleucel | Phase 1 | Recruiting | Washington University School of Medicine | Sep 30, 2025 |
| A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel | Ciltacabtagene autoleucel | Phase 2 | Recruiting | Janssen Research & Development, LLC | Sep 2, 2025 |
| Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma | Ciltacabtagene autoleucel | Phase 1 | Recruiting | Medical College of Wisconsin | Jul 30, 2025 |
| A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible | Idecabtagene vicleucel | Not applicable | Not yet recruiting | Xuzhou Medical University | Jul 17, 2025 |
| CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients? | Idecabtagene vicleucel | Phase 2 | Not yet recruiting | Xuzhou Medical University | Jul 17, 2025 |
| Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma | Ciltacabtagene autoleucel | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | Apr 27, 2025 |
| Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma | Idecabtagene vicleucel | Phase 1 | Not yet recruiting | Xuzhou Medical University | Apr 6, 2025 |
| The Norwegian Immunotherapy in Multiple Myeloma Study | Idecabtagene vicleucel | — | Recruiting | St. Olavs Hospital | Mar 3, 2025 |